169 related articles for article (PubMed ID: 25437196)
1. Total lesion glycolysis as an IgG4-related disease activity marker.
Nakatsuka Y; Handa T; Nakamoto Y; Nobashi T; Yoshihuji H; Tanizawa K; Ikezoe K; Sokai A; Kubo T; Hirai T; Chin K; Togashi K; Mimori T; Mishima M
Mod Rheumatol; 2015 Jul; 25(4):579-84. PubMed ID: 25437196
[TBL] [Abstract][Full Text] [Related]
2. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease.
Berti A; Della-Torre E; Gallivanone F; Canevari C; Milani R; Lanzillotta M; Campochiaro C; Ramirez GA; Bozzalla Cassione E; Bozzolo E; Pedica F; Castiglioni I; Arcidiacono PG; Balzano G; Falconi M; Gianolli L; Dagna L
Rheumatology (Oxford); 2017 Dec; 56(12):2084-2092. PubMed ID: 28977663
[TBL] [Abstract][Full Text] [Related]
3. Utility of FDG-PET/CT in the diagnosis of IgG4-related diseases.
Zhao Z; Wang Y; Guan Z; Jin J; Huang F; Zhu J
Clin Exp Rheumatol; 2016; 34(1):119-25. PubMed ID: 26842851
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
5. The utility of FDG-PET/CT and other imaging techniques in the evaluation of IgG4-related disease.
Takahashi H; Yamashita H; Morooka M; Kubota K; Takahashi Y; Kaneko H; Kano T; Mimori A
Joint Bone Spine; 2014 Jul; 81(4):331-6. PubMed ID: 24568886
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study.
Ebbo M; Grados A; Guedj E; Gobert D; Colavolpe C; Zaidan M; Masseau A; Bernard F; Berthelot JM; Morel N; Lifermann F; Palat S; Haroche J; Mariette X; Godeau B; Bernit E; Costedoat-Chalumeau N; Papo T; Hamidou M; Harlé JR; Schleinitz N
Arthritis Care Res (Hoboken); 2014 Jan; 66(1):86-96. PubMed ID: 23836437
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
8. Role of F-18 FDG PET/CT in assessing IgG4-related disease with inflammation of head and neck glands.
Tokue A; Higuchi T; Arisaka Y; Nakajima T; Tokue H; Tsushima Y
Ann Nucl Med; 2015 Jul; 29(6):499-505. PubMed ID: 25877159
[TBL] [Abstract][Full Text] [Related]
9. Disease activity and response to therapy monitored by [
Mitamura K; Arai-Okuda H; Yamamoto Y; Norikane T; Takami Y; Fujimoto K; Wakiya R; Ozaki H; Dobashi H; Nishiyama Y
EJNMMI Res; 2020 Dec; 10(1):153. PubMed ID: 33296037
[TBL] [Abstract][Full Text] [Related]
10. Utility of FDG PET/CT for Differential Diagnosis of Patients Clinically Suspected of IgG4-Related Disease.
Lee J; Hyun SH; Kim S; Kim DK; Lee JK; Moon SH; Cho YS; Choe YS; Kim BT; Lee KH
Clin Nucl Med; 2016 May; 41(5):e237-43. PubMed ID: 26914555
[TBL] [Abstract][Full Text] [Related]
11. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
[TBL] [Abstract][Full Text] [Related]
12. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
Sun Y; Lu P; Yu L
Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
15. Characterizing IgG4-related disease with ¹⁸F-FDG PET/CT: a prospective cohort study.
Zhang J; Chen H; Ma Y; Xiao Y; Niu N; Lin W; Wang X; Liang Z; Zhang F; Li F; Zhang W; Zhu Z
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1624-34. PubMed ID: 24764034
[TBL] [Abstract][Full Text] [Related]
16. Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary.
Takeuchi S; Lucchini M; Schmeler KM; Coleman RL; Gershenson DM; Munsell MF; Macapinlac HA; Ramirez PT
Gynecol Oncol; 2014 Apr; 133(1):100-4. PubMed ID: 24534359
[TBL] [Abstract][Full Text] [Related]
17. Volumetric comparison of positron emission tomography/computed tomography using 4'-[methyl-¹¹C]-thiothymidine with 2-deoxy-2-¹⁸F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma.
Ito K; Yokoyama J; Miyata Y; Toyohara J; Okasaki M; Minamimoto R; Morooka M; Ishiwata K; Kubota K
Nucl Med Commun; 2015 Mar; 36(3):219-25. PubMed ID: 25369751
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
Ogawa S; Itabashi M; Kondo C; Momose M; Sakai S; Kameoka S
Anticancer Res; 2015 Jun; 35(6):3495-500. PubMed ID: 26026116
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of
Bai Z; Zhou T; Yu Z; Chen Y; Dong L
Ann Nucl Med; 2022 Jul; 36(7):651-660. PubMed ID: 35604531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
